Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcriptome analysis following Apigenin and Chrysin treatment of Mouse Embryonic Fibroblasts

ABSTRACT: Transcriptome analysis following Apigenin and Chrysin treatment of Mouse Embryonic Fibroblasts

PROVIDER: PRJNA655832 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR12407348_1.fastq.gz	Fastqsanger.gz
	SRR12407348_2.fastq.gz	Fastqsanger.gz
	SRR12407349_1.fastq.gz	Fastqsanger.gz
	SRR12407349_2.fastq.gz	Fastqsanger.gz
	SRR12407350_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 48

Similar Datasets

Transcriptome analysis following Apigenin and Chrysin treatment of Mouse Embryonic Fibroblasts

Project description:There is no known single therapeutic drug for treating hypercholesterolemia that comes with negligible systemic side effects. In the current study, using next generation RNA sequencing approach in mouse embryonic fibroblasts we discovered that two structurally related flavonoid compounds, Apigenin and Chrysin exhibited moderate blocking ability of multiple transcripts that regulate rate limiting enzymes in the cholesterol biosynthetic pathway. The observed decrease in cholesterol biosynthesis pathway correlated well with an increase in transcripts involved in generation and trafficking of ketone bodies as evident by the upregulation of Bdh1 and Slc16a6 transcripts. Impact statement - The hypocholesterolemic potential of Apigenin and Chrysin at higher concentrations along with their ability to generate ketogenic substrate especially during embryonic stage is useful or detrimental for embryonic health is not clear and still debatable. Our findings will set the stage for translating this information to whole animal and clinical studies that could shed light to the existing information regarding safe use of Apigenin and Chrysin, specifically to embryonic health.

2021-08-09 | GSE155852 | GEO

Differential gene expression in mice liver following apigenin administration

Project description:Differential gene expression in mice liver after apigenin administration. Gene expression from control mice were compared with apigenin treated mice at different dose level.

2011-04-27 | GSE12716 | GEO

Differential gene expression in mice liver following apigenin administration

Project description:Differential gene expression in mice liver after apigenin administration. Gene expression from control mice were compared with apigenin treated mice at different dose level. To study differential expression primarily at high stringency and in dose dependent manner was to increase the statistical confidence in the detection of important genes and cellular processes with a probable role in the initiation and propagation of toxicity as well as those possibly involved in regeneration during the early phase of tissue response.

2011-04-27 | E-GEOD-12716 | biostudies-arrayexpress

The transcriptome sequencing of Chrysin treated Scc9 Extracellular vesicles

Project description:EVs-Chrysin(Chrysin-treated SCC9) were isolated from SCC9 cells that were treated with chrysin. To improve the therapeutic effect, AuNPs were carried by EVs-Chrysin (Au-EVs). Compared to BGC823 and HCC-LM3 cells, the uptake of Au-EVs were specific in SCC9 cells. Moreover, Au-EVs combined with NIR enhanced cell apoptosis in TSCC cells. To confirm the role of miRNAs in cell apoptosis, the differentially expressed miRNAs between EVs-Con and EVs-Chrysin were screened by RNA-seq.

2021-10-12 | GSE185562 | GEO

The RNA-seq result of GC cells which were treated with chrysin

Project description:Chrysin has been reported to have anticancer effect. We used 40μM chrysin to treat SGC7901 cells for 48h, then sequenced their RNA, analyzed the differentially expressed genes before and after treatment, screened out the anticancer target of chrysin, and then carried on the next analysis

2021-08-19 | GSE181492 | GEO

Gene expression signatures for apigenin treatment in human AML cell lines

Project description:To investigate the effect of apigenin on gene expression, we have employed whole genome microarray expression profiling as a discovery platform to identify genes with the potential to suppress the cell proliferation of human acute myeloid leukemia (AML) cell lines. HL-60 amn NB4 cells were treated with apigenin for 24 h in vitro.

2022-03-31 | GSE193798 | GEO

The effects of apigenin on microRNA expression levels

Project description:The changes of mature microRNA expression levels after apigenin treatment on Huh7 cells were determined. Huh7 cells were treated with 10microM apigenin for 24hr and the changes of global mature microRNA expression levels were determined.

2013-08-20 | E-GEOD-46526 | biostudies-arrayexpress

Comprehensive transcriptome analysis of lung tissues in the sugen/hypoxia rats with/without treatment of chrysin or trimetazidine

Project description:Pulmonary arterial hypertension (PAH) is a debilitating progressive disease characterized by high blood pressure in the pulmonary artery. Chrysin (5,7-dihydroxyflavone) is a phytochemical, which is a flavonoid widely present in plant sources. It is known that right ventricular dysfunction is the worst mortality predictor in patient with PAH. Recent studies have shown that chrysin improves hemodynamic parameters including right ventricular pressure, right ventricular hypertrophy, and pulmonary vascular remodeling in a rat model of chronic hypoxia-induced pulmonary hypertension. On the other hand, trimetazidine (TMZ) is an anti-ischemic agent widely used in the treatment of coronary artery disease. It has been reported that trimetazidine therapy for 3 months on top of standard PAH regime significantly improve right ventricular ejection fraction and functional capacity in patient with PAH. However, the effects of chrysin or trimetazidine on gene expression in lung of patient with PAH. Here, we performed that a comprehensive analysis of gene expression changes in lung tissues of sugen-received rats under hypoxic conditions, which is a model of PAH with chrysin or trimetazidine treatment using RNA sequencing (RNA-seq).

2024-05-16 | GSE186996 | GEO

Comprehensive transcriptome analysis of heart tissues in the sugen/hypoxia rats with/without treatment of chrysin

Project description:Pulmonary arterial hypertension (PAH) is a progressive disease characterized by pulmonary vascular remodeling leading to increased pulmonary vascular resistance and right ventricular (RV) hypertrophy, resulting in RV failure. RV dysfunction is a complex process that leads to cardiomyocyte hypertrophy, fibrosis, inflammation, angiogenesis, and metabolic changes. In patient with PAH, the adaptation of the RV to high pulmonary arterial pressures is the most important determinant of prognosis. However, the underlying molecular mechanism of adverse RV remodeling and dysfunction is poorly understood, and there are no currently approved therapies that improve RV function. Chrysin (5,7-dihydroxyflavone) is a phytochemical, which is a flavonoid widely present in plant sources. In various experimental models chrysin has shown to exert cardio-protective effects through its antioxidant and anti-inflammatory effects. In this study, we performed a comprehensive analysis of gene expression changes in heart tissues of rats under hypoxic conditions with chrysin treatment using RNA sequencing (RNA-seq).

2022-02-15 | GSE186989 | GEO

Apigenin inhibits tumor angiogenesis by suppressing microvesicle biogenesis

Project description:Apigenin regulates multiple pathways related to microvesicle biogenesis without affecting the expression of small Rho GTPase activator guanine nucleotide exchange factors (GEFs). However, apigenin can primarily targets ARHGEF1 protein, a GEF of the small GTPases, thereby inhibiting the activity of small G proteins such as Cdc42, which is essential in regulating the signaling for the release of microvesicles from tumor cells. Targeting ARHGEF1, apigenin effectively prevents tumor cells from releasing microvesicles. This, in turn, inhibits tumor angiogenesis related to VEGF90K transport on microvesicles, ultimately impeding tumor progression.

2024-07-22 | GSE251817 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data